In this webinar, two drug policy professionals from Community Impact North Carolina and the Center for U.S. Policy discussed recent and anticipated federal legislative and regulatory changes, and their likely impacts on substance use disorder (SUD) prevention, treatment, recovery, and harm reduction. The speakers addressed which COVID-19 PHE regulatory flexibilities would likely be made permanent, and which would probably be rolled back.
Additional topics included a new law facilitating research on the potentially therapeutic properties of cannabinoids, the elimination of the DATA 2000 waiver requirement for prescribers of buprenorphine for opioid use disorder (OUD), FDA’s approval of the first over-the-counter naloxone nasal spray, and new rules that would affect access to methadone for OUD. Lastly, the speakers analyzed a recent report that provided a glimmer of hope that substance misuse may be in decline.
View the webinar slides here.